2015 American Transplant Congress
Glycogen Synthase Kinase 3β Inhibition Promotes Human iTreg Differentiation and Suppressive Function
The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Induced regulatory T cells (iTregs) are essential to maintain immunological tolerance, immune homeostasis, and prevention of autoimmunity. Some studies suggest that glycogen synthase kinase 3β…2015 American Transplant Congress
Improved Bioavailability and Reduced Dose Requirements of Novel, Once-Daily, MeltDose® Tacrolimus Formulation Tablets (Envarsus® XR) Compared to Twice-Daily Tacrolimus Capsules (Prograf®) in De Novo Kidney Transplantation: Results of a Phase 3 Double-Dummy, Randomized Trial
Tacrolimus (tac) is an immunosuppressive drug with a narrow therapeutic range. Adequate trough levels following kidney transplantation (≥6 ng/mL depending on regimen and time post-transplant)…2015 American Transplant Congress
First Dose Tacrolimus Level Is Better Than CYP3A5 Genotyping in Prediction of Target Tacrolimus Dose
Background: Tacrolimus dose highly varies among Asian kidney transplant recipients. This can be explained by variety of CYP3A5 expression. CYP3A5 genotyping is highly recommended for…2015 American Transplant Congress
Expanding the Living Donor Pool: Results of ABO Incompatible Living Related Kidney Transplantation
Background: Organ shortage has led to an increase in living related kidney transplantation. Here we report on our program of expanding the living donor pool…2015 American Transplant Congress
Alloimmune Regulation and Long-Term Allograft Survival Induced by Short-Term Administration of Chinese Medicine Cornus Officinalis and Cuscuta Sinensis Lam
Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, China.
Achieving long-term allograft survival or tolerance without continuously global immunosuppression is a highly desirable goal. This study is to induce long-term allograft survival without long-term…2015 American Transplant Congress
Once-a-Day Administration of CNIs, mTOR and MMF Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study
Surgery - Renal Transplant Unit, Catholic University of the Sacred Heart, Rome, Italy.
Introduction. The half-lives of Tacrolimus, Everolimus, Cyclosporine and Mofetil Micofenolate (MMF) are respectively: 43, 30, 27 and 18 hours. Once-daily dosing of these drugs is…2015 American Transplant Congress
12-Month Athena Study: Everolimus Vs. Standard Regimen in De Novo Renal Transplant Recipients
1Athena Study Group, Germany; 2Novartis, Pharma, Germany.
Background: Post-kidney transplant (KTx) long-term and full dose/standard calcineurin inhibitor (CNI) use is associated with an increased risk for malignancies, cardiovascular disease, and renal failure.…2015 American Transplant Congress
Liver Allograft Provides Immunoprotection for the Cardiac Allograft in Combined Heart-Liver Transplantation
When transplanted simultaneously, the liver allograft has been thought to have an immunoprotective role on other organs. However, detailed studies on simultaneous heart-liver transplantation (SHLT)…2015 American Transplant Congress
Pancreas Transplantation Immunosuppression Induction With Rabbit Antithymocyte Globulin +/- Rituximab and Early Steroid Withdrawal: Experience With >500 Recipients
T-cell depleting antibody induction, often combined with steroid withdrawal, has become standard practice for pancreas transplantation. In this study, outcomes of >500 pancreas transplants using…2015 American Transplant Congress
Improved Long-Term Graft Survival in Renal Transplant Recipients With Donor Specific Antibodies (DSA) After Mycophenolic Acid Escalation
Background: DSA formation in post-renal transplant patients is associated with chronic rejection and graft failure. Previous studies in our population indicate DSA formation is a…
- « Previous Page
- 1
- …
- 129
- 130
- 131
- 132
- 133
- …
- 138
- Next Page »